Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy

David Estin, Mingwei Li, David C. Spray, Julian K. Wu

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

OBJECTIVE: Experimental brain tumor gene therapy with the herpes simplex virus thymidine kinase (HSV-tk) gene has demonstrated that not only HSV-tk transduced but surrounding non-HSV-tk transduced cells are killed when given ganciclovir. This so-called bystander effect has recently been shown to be dependent on connexin-mediated intercellular communication. To assess potential susceptibility to the bystander effect, we examined levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Connexin-26 expression has not previously been studied in primary brain tumors and connexin-43 expression has not been studied in nonastrocytic primary brain tumors. We also attempted to enhance the bystander effect in vitro by overexpressing connexin in tumor cells with high basal levels of connexin expression. METHODS: Western blot analysis and immunohistochemistry were used to determine levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Wild-type 9L gliosarcoma cells were transfected in vitro with the connexin-43 gene and the HSV-tk gene or the HSV-tk gene alone. The bystander effect of each transfectant was then assessed and compared. RESULTS: Most of the primary brain tumors tested, including low-grade astrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas, gangliogliomas, meningiomas, and medulloblastomas, showed connexin-26 and connexin-43 expression. Bystander experiments revealed a significant enhancement of the bystander effect in the gliosarcoma cells transfected with connexin-43 and HSV-tk, as compared with gliosarcoma cells transfected with HSV-tk alone. CONCLUSION: Most primary brain tumors express connexin-26 and connexin-43. This suggests that most primary brain tumors may be susceptible to the bystander effect of HSV-tk gene therapy. The bystander effect can be enhanced in vitro by overexpression of connexin-43 in a cell line with a high basal level of connexin-43 expression.

Original languageEnglish (US)
Pages (from-to)361-369
Number of pages9
JournalNeurosurgery
Volume44
Issue number2
DOIs
StatePublished - Feb 1999

Fingerprint

Bystander Effect
Connexin 43
Connexins
Thymidine Kinase
Brain Neoplasms
Genetic Therapy
Simplexvirus
Gliosarcoma
Astrocytoma
Genes
Ganglioglioma
Oligodendroglioma
Medulloblastoma
Ganciclovir
Meningioma
Glioblastoma
Western Blotting
Immunohistochemistry
Connexin 26
Viruses

Keywords

  • Brain tumor
  • Connexin-26
  • Connexin-43
  • Gene therapy
  • Glioma
  • Herpes simplex virus thymidine kinase

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. / Estin, David; Li, Mingwei; Spray, David C.; Wu, Julian K.

In: Neurosurgery, Vol. 44, No. 2, 02.1999, p. 361-369.

Research output: Contribution to journalArticle

Estin, David ; Li, Mingwei ; Spray, David C. ; Wu, Julian K. / Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. In: Neurosurgery. 1999 ; Vol. 44, No. 2. pp. 361-369.
@article{f28c9cf2f556429cbc3e973a3211c5b0,
title = "Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy",
abstract = "OBJECTIVE: Experimental brain tumor gene therapy with the herpes simplex virus thymidine kinase (HSV-tk) gene has demonstrated that not only HSV-tk transduced but surrounding non-HSV-tk transduced cells are killed when given ganciclovir. This so-called bystander effect has recently been shown to be dependent on connexin-mediated intercellular communication. To assess potential susceptibility to the bystander effect, we examined levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Connexin-26 expression has not previously been studied in primary brain tumors and connexin-43 expression has not been studied in nonastrocytic primary brain tumors. We also attempted to enhance the bystander effect in vitro by overexpressing connexin in tumor cells with high basal levels of connexin expression. METHODS: Western blot analysis and immunohistochemistry were used to determine levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Wild-type 9L gliosarcoma cells were transfected in vitro with the connexin-43 gene and the HSV-tk gene or the HSV-tk gene alone. The bystander effect of each transfectant was then assessed and compared. RESULTS: Most of the primary brain tumors tested, including low-grade astrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas, gangliogliomas, meningiomas, and medulloblastomas, showed connexin-26 and connexin-43 expression. Bystander experiments revealed a significant enhancement of the bystander effect in the gliosarcoma cells transfected with connexin-43 and HSV-tk, as compared with gliosarcoma cells transfected with HSV-tk alone. CONCLUSION: Most primary brain tumors express connexin-26 and connexin-43. This suggests that most primary brain tumors may be susceptible to the bystander effect of HSV-tk gene therapy. The bystander effect can be enhanced in vitro by overexpression of connexin-43 in a cell line with a high basal level of connexin-43 expression.",
keywords = "Brain tumor, Connexin-26, Connexin-43, Gene therapy, Glioma, Herpes simplex virus thymidine kinase",
author = "David Estin and Mingwei Li and Spray, {David C.} and Wu, {Julian K.}",
year = "1999",
month = "2",
doi = "10.1097/00006123-199902000-00068",
language = "English (US)",
volume = "44",
pages = "361--369",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy

AU - Estin, David

AU - Li, Mingwei

AU - Spray, David C.

AU - Wu, Julian K.

PY - 1999/2

Y1 - 1999/2

N2 - OBJECTIVE: Experimental brain tumor gene therapy with the herpes simplex virus thymidine kinase (HSV-tk) gene has demonstrated that not only HSV-tk transduced but surrounding non-HSV-tk transduced cells are killed when given ganciclovir. This so-called bystander effect has recently been shown to be dependent on connexin-mediated intercellular communication. To assess potential susceptibility to the bystander effect, we examined levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Connexin-26 expression has not previously been studied in primary brain tumors and connexin-43 expression has not been studied in nonastrocytic primary brain tumors. We also attempted to enhance the bystander effect in vitro by overexpressing connexin in tumor cells with high basal levels of connexin expression. METHODS: Western blot analysis and immunohistochemistry were used to determine levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Wild-type 9L gliosarcoma cells were transfected in vitro with the connexin-43 gene and the HSV-tk gene or the HSV-tk gene alone. The bystander effect of each transfectant was then assessed and compared. RESULTS: Most of the primary brain tumors tested, including low-grade astrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas, gangliogliomas, meningiomas, and medulloblastomas, showed connexin-26 and connexin-43 expression. Bystander experiments revealed a significant enhancement of the bystander effect in the gliosarcoma cells transfected with connexin-43 and HSV-tk, as compared with gliosarcoma cells transfected with HSV-tk alone. CONCLUSION: Most primary brain tumors express connexin-26 and connexin-43. This suggests that most primary brain tumors may be susceptible to the bystander effect of HSV-tk gene therapy. The bystander effect can be enhanced in vitro by overexpression of connexin-43 in a cell line with a high basal level of connexin-43 expression.

AB - OBJECTIVE: Experimental brain tumor gene therapy with the herpes simplex virus thymidine kinase (HSV-tk) gene has demonstrated that not only HSV-tk transduced but surrounding non-HSV-tk transduced cells are killed when given ganciclovir. This so-called bystander effect has recently been shown to be dependent on connexin-mediated intercellular communication. To assess potential susceptibility to the bystander effect, we examined levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Connexin-26 expression has not previously been studied in primary brain tumors and connexin-43 expression has not been studied in nonastrocytic primary brain tumors. We also attempted to enhance the bystander effect in vitro by overexpressing connexin in tumor cells with high basal levels of connexin expression. METHODS: Western blot analysis and immunohistochemistry were used to determine levels of connexin-26 and connexin-43 expression in a series of primary brain tumors. Wild-type 9L gliosarcoma cells were transfected in vitro with the connexin-43 gene and the HSV-tk gene or the HSV-tk gene alone. The bystander effect of each transfectant was then assessed and compared. RESULTS: Most of the primary brain tumors tested, including low-grade astrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas, gangliogliomas, meningiomas, and medulloblastomas, showed connexin-26 and connexin-43 expression. Bystander experiments revealed a significant enhancement of the bystander effect in the gliosarcoma cells transfected with connexin-43 and HSV-tk, as compared with gliosarcoma cells transfected with HSV-tk alone. CONCLUSION: Most primary brain tumors express connexin-26 and connexin-43. This suggests that most primary brain tumors may be susceptible to the bystander effect of HSV-tk gene therapy. The bystander effect can be enhanced in vitro by overexpression of connexin-43 in a cell line with a high basal level of connexin-43 expression.

KW - Brain tumor

KW - Connexin-26

KW - Connexin-43

KW - Gene therapy

KW - Glioma

KW - Herpes simplex virus thymidine kinase

UR - http://www.scopus.com/inward/record.url?scp=0032929652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032929652&partnerID=8YFLogxK

U2 - 10.1097/00006123-199902000-00068

DO - 10.1097/00006123-199902000-00068

M3 - Article

C2 - 9932890

AN - SCOPUS:0032929652

VL - 44

SP - 361

EP - 369

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 2

ER -